Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma

Overview of attention for article published in Frontiers in oncology, November 2023

Altmetric Badge

Mentioned by

So far, Dimensions has found 1 citation of this research output.

The most recent citing publication is shown below. View this citation on Dimensions.

Article in Frontiers in Public Health (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.